ILMN vs RNA · rev $2.25B vs rev $22.6M
Illumina Inc (ILMN) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Illumina Inc (ILMN) is a diagnostics & research company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported ILMN revenue for 2026-06-28 was $2.25B. Net income was $340.0M. ILMN currently screens at market cap $15.84B.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
ILMN currently screens at market cap $15.84B. RNA currently screens at market cap $217.5M.
Not investment advice. Open the ILMN and RNA stock pages for the full models.
Not investment advice.